You are here
Perspectives from the California Institute for Regenerative Medicine
Debilitating eye diseases represent a large unmet medical need potentially addressable by stem cell-based approaches. This article describes the advances made over the past 10 years by California Institute for Regenerative Medicine-supported grantees in developing and translating stem cell-based therapies for dry age-related macular degeneration, retinitis pigmentosa, and limbal stem cell deficiency. The approaches described are now under evaluation in the clinic or have obtained approval to begin a clinical trial.
First published: September 13, 2021. https://doi.org/10.1002/sctm.21-0239
At California Institute for Regenerative Medicine's (CIRM) inception, the potential of human stem cells to alleviate disease was clear. However, the inaccessibility of relevant living human cells for study stymied the understanding of human disease. Clinically appropriate manufacturing methods, quality control tools, animal models to evaluate cell therapies, and delivery tools for living products were limiting. CIRM's comprehensive vision to build the stem cell therapy field by investing in the development of tools and technologies required to support this emerging discipline has resulted in the examples of successfully developed tools discussed in this perspective. These tools are helping to realize stem cell therapy's promise.
First published: July 03, 2020. https://doi.org/10.1002/sctm.20-0079
For cell and tissue therapies to become widely accessible will ultimately require the success of off‐the‐shelf allogeneic products that can be administered to patients regardless of immune compatibility with the donor tissue. Since the long‐term use of immunosuppressive drugs renders patients subject to infectious disease and other side effects, it is critical to develop alternative methods to overcome immune barriers to engraftment. The California Institute for Regenerative Medicine (CIRM) has funded multiple programs, in different disease areas and at different stages of therapeutic development, that are tackling this challenge. Herein, we summarize the main approaches that are being taken in this rapidly moving field and gives examples of specific programs that CIRM has funded in these different areas.
First published: June 25, 2020. https://doi.org/10.1002/sctm.20-0079